Non-small-cell lung cancer (NSCLC) prognosis is stnrctly related to well-established clinicopathological parameters which have unfortunately become insufficient in the prognostic evaluation of this type of cancer. As p53 and bcl-2 gene deregulations are frequently involved in several types of epithelial malignancies, we investigated the Bcl-2 and p53 protein expression in 91 and 101 cases of NSCLC respectively. The expression was then compared with established indicators of prognosis and biological behaviour of the tumours. No relationship was observed between Bcl-2 and either clinicopathological or biological parameters such as histology, grading, tumour status, nodal metastasis and proliferative activity evaluated by scoring proliferating cell nuclear antigen expression and Ki-67 immunoreactivity. However, the mean Bcl-2 expression was significantly lower in patients who developed metastasis during follow-up or died of metastatic disease (P = 0.006 and P= 0.01 respectively). Moreover, survival probability was higher in patients who expressed the Bcl-2 protein (P =0.0002). In contrast with this, p53 protein accumulation was observed in tumours with metastatic nodal involvement (P = 0.02) or in patients who developed metastasis during follow-up (P = 0.01), although no correlation was found between p53 expression and overall survival. An inverse relationship was also found between Bcl-2 and the anti-oncogene protein product p53 (P = 0.01). Thus, a high proportion of NSCLCs express p53 and Bcl-2 proteins and their expression may have prognostic importance.
Lung cancer has now become the leading cause of cancer deaths in both men and women in the USA (Minna et al., 1989) . In particular, non-small-cell lung cancer (NSCLC) represents a heterogeneous subgroup in terms of both behaviour and therapeutic response. Several studies have clearly demonstrated that multiple genetic events are associated with the development of lung cancer, including a range of chromosomal abnormalities, mutations activating the dominant cellular proto-oncogenes and genetic events inactivating tumour suppressor genes (Minna, 1993) . p53 alterations and aberrant nuclear accumulation of this protein have been recently studied with particular interest. Many experimental data indicate that the p53-suppressor gene is the most commonly altered tumour-suppressor gene (Hollstein et al., 1991) . This gene codes for a nuclear phosphoprotein, normally undetectable in human cells, which is able to regulate cell growth and division (Levine et al., 1991; Lane, 1992) . p53 protein may be detected by immunocytochemistry in cancer cells as a consequence either of mutational events in p53 gene or of stabilisation by other factors such as some viral proteins. p53 alterations appear early during NSCLC progression; these alterations are maintained during invasion and metastatic spread of cancer cells (Quinlan et al., 1992; Fontanini et al., 1994) , inducing a proliferative advantage and conferring a particularly aggressive phenotype.
The bcl-2 gene was originally discovered owing to its involvement in the t(14;18) chromosomal translocation occurring in the majority of non-Hodgkin's B-cell lymphomas (Tsujimoto and Croce, 1986; Aisemberg et al., 1988) . This translocation places the bcl-2 gene at chromosomal location 18q21 in juxtaposition with the immunoglobulin heavy-chain locus at 14q32, resulting in transcriptional deregulation of the bcl-2 gene (Cleary et al., 1984; Tsujimoto and Croce, 1986; Tsujimoto et al., 1987) (Leek et al., 1994) .
The high incidence of p53 alterations and the aberrant expression of Bcl-2 in many human cancers together with their putative prognostic significance in lung (Pezzella et al., 1993a) and breast cancer (Silvestrini et al., 1994) Table I , no statistical differences in Bcl-2 expression were found between: (1) tumour histotype, (2) tumour grade, (3) tumour status and (4) nodal metastasis.
Bcl-2 expression and proliferative activity Highly proliferating tumours (cut-off 30% for PCNA and 13% for Ki-67) express a percentage of positive cells similar to that of tumours with low proliferative activity (Table II) . These results suggest that the Bcl-2 protein expression is independent of the proliferative status of the tumours.
Bcl-2 expression in relation to distant metastasis and survival In 89 out of 91 patients the data regarding development of metastases and overall survival were available (two patients died during the post-operative period). In order to determine whether the alterations in the Bcl-2 protein may be a prognostic indicator in NSCLC, we analysed Bcl-2 expression both in tumours from patients with and without metastases and in patients still alive or dead from neoplastic disease. Bcl-2 expression was significantly higher (P<0.006) in tumours from metastasis-free patients than in tumours from patients with distant metastases. We also found that tumours from living patients presented a higher number of Bcl-2-immunoreactive cells than tumours from dead patients (P<0.01) ( Table III) . The same results obtained from survival analysis are reported in Figure 2a . NSCLC patients with Bcl-2-positive tumours had a higher probability of survival than patients with Bcl-2-negative cancers (KaplanMeier analysis, P= 0.0002). We obtained the same results (Figure 2b ; Kaplan-Meier method).
Bcl-2 and p53 protein expression
Staining for both Bcl-2 and p53 was available in 90 cases.
The results are summarised in Table VII . Of 60 Bcl-2-positive tumours, 60% showed p53 overexpression, whereas of 30 Bcl-2-negative tumours 87% showed p53 immunoreactivity (P= 0.01). Regression analysis is reported in Figure 3 ; a clear inverse correlation was found between the p53 and Bcl-2 protein expression (P = 0.01).
Bcl-2 and p53 proteins are both related to programmed cell death or apoptosis and thus their relationship is of interest. In this series of NSCLCs the results showed that Bcl-2 and p53: (a) are detectable by the immunohistochemical technique in about 60% and 70% of cases respectively; (b) are inversely associated; and (c) provide information regarding metastasis onset and overall survival probability. Bcl-2 represents the product of the proto-oncogene involved in the 14;18 translocation; its distribution in reactive lymph nodes and lymphomas has already been described (Villeundas et al., 1992; Pezzella et al., 1993b; Piris et al., 1994) . Bcl-2 expression has been observed not only in the B-lymphoma but also in different types of solid tumours such as breast (Leek et al., 1994; Silvestrini et al., 1994) , prostate (Colombel et al., 1993) thyroid (Pilotti et al., 1994) and lung cancer (Pezzella et al., 1993a) .
In particular, in NSCLCs, which are believed to orginate from the respiratory epithelium, Bcl-2 overexpression was related with better overall survival (Pezzella et al., 1993a gression. However, this hypothesis cannot be confirmed in lung cancer since we failed to find any differences in the Bcl-2 expression of tumours of different grade. It is known that Bcl-2 promotes cell survival even when the cell proliferation rate is not elevated. This could provide a growth advantage eventually leading to neoplastic transformation (Vaux et al., 1988) . McDonnel et al. (1989) suggested that for cellular clones in which a low proliferative rate is offset by Bcl-2 expression the acquisition rate of complementary defects is slower than in clones with a higher proliferative rate. The association of a growth advantage owing to cellular survival with low proliferative rate and slower acquisition of further genetic defects could explain the slow evolution of follicular lymphoma in which Bcl-2 expression is a frequent primary aberration (Vaux et al., 1988; McDonnel et a!., 1989) . Different authors have suggested recently that alterations in Bcl-2 could be present as a frequent aberration not only in follicular lymphoma (Korsmeyer, 1992) , but also in other types of cancer such as breast (Silvestrini et al., 1994; Leek et al., 1994) and lung (Pezzella et al., 1993a) carcinomas. This relation could be responsible for the increasing likelihood of mutational aberrations in other oncogenes, such as those interfering with growth and proliferation of tumour cells.
Our observations of a subgroup of patients with slowly progressing Bcl-2-positive tumours suggest that in these tumours Bcl-2 expression is likely to occur as an initial alteration kading to a less aggressive behaviour of tumours. This is in agreement with the inverse relationship between Bcl-2 and p53 which we found in our series of cancers, supporting the hypothesis that either one or the other is sufficient to modify the apoptotic pathway in NSCLC.
In our study Bcl-2 expression is not associated with cell proliferation evaluated as a percentage of PC1O-or Ki-67-immunoreactive cells. In addition, we found that the bronchial epithelium expresses Bcl-2 in a proportion of basal cells, and that there is a total lack of Bcl-2-positive cells in the upper differentiated layers of the epithelium although hyperplasia is sometimes present in these areas. These findings have been confirmed by Lu et al. (1993) , who have recently reported the lack of Bcl-2 expression in non-proliferating syncytiotrophoblast and in psorasis despite evident mitoti activity. This suggests that Bcl-2 is mainly associated with activated and undifferentiated cells undergoing terminal differentiation which need protection from apoptosis.
p53 is now well characterised as a tumour-suppressor gene, with loss of normal p53 function recorded as the most common genetic event associated with human malignancies (Hollstein, 1991 Bcl-2 and p53 in NSCLC prognosis G Fontanini et al 1007 poor prognosis in some solid tumours such as breast (Thor et al., 1992; Allred et al., 1993; Silvestrini et al., 1993) , gastric (Martin et al., 1992) , bladder (Sarkis et al., 1993) and lung (Quinlan et al., 1992) carcinomas. In a series of 103 NSCLCs (Fontanini et al., 1993a) we found that p53 protein overexpression correlated with metastatic involvement of hilar and/ or mediastinal lymph nodes, supporting other findings by Quinlan et al. about the negative prognostic role of p53 alterations in NSCLC. In this group of patients it was confirmed that p53 accumulation may predict the metastatic behaviour of NSCLC, and that it is overexpressed not only in cancer with nodal metastatic involvement at diagnosis but also in tumours which develop distant metastases during follow-up. Our present results indicate on the one hand an inverse relationship between Bcl-2 and p53 expression and, on the other hand, an inverse prognostic significance of these variables in NSCLC behaviour. The loss of Bcl-2 expression is in fact associated with shorter overall survival, metastatic development during follow-up and other poor prognostic markers such as p53 positivity. For this reason, the role of Bcl-2 in lung cancer progression may differ from that seen in lymphomas in which the translation 14;18 occurs.
Further efforts are needed to assess the prognostic significance of Bcl-2 and its relation with other gene products involved in the regulation of apoptosis and proliferation.
